Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%

MT Newswires Live

2025/08/04

Chimeric Therapeutics (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.

Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.

The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.

Its shares fell 14% in recent trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556877445"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556877445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556877445?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 12:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556877445","market":"fut","top_or_hot":-1,"title":"Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CHM.AU\">Chimeric Therapeutics</a> (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.</p><p>Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.</p><p>The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.</p><p>Its shares fell 14% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-04 12:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CHM.AU\">Chimeric Therapeutics</a> (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.</p><p>Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.</p><p>The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.</p><p>Its shares fell 14% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHM.AU","symbol_name":"CHIMERIC THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2556877445","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556877445","pubTimestamp":1754283189,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chimeric Therapeutics  said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.Its shares fell 14% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CHM.AU":"CHIMERIC THERAPEUTICS LTD","LENZ":"Therapeutics","BK4139":"生物科技","BK7067":"生物科技","BK4007":"制药","BK4539":"次新股"},"translate_title":"Chimeric Therapeutics称肿瘤候选治疗研究进展至第二剂量水平，股价下跌14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHM.AU":0.9,"LENZ":1},"content_text":"Chimeric Therapeutics (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.Its shares fell 14% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}